STX10

Across TCGA pan-cancer cohorts, STX10 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of STX10’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where STX10 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types STX10 is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where STX10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STX10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.163	<.001	7	view →
COAD	Male	All	+0.351	.009	4	view →
LSCC	Male	All	−0.082	.009	3	view →
PDAC	All	All	−0.208	.037	1	view →
LUAD	All	All	+0.084	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

STX10–CCRCC

Open the CCRCC breakdown →